Pfizer Inc. (PFE)
Pfizer Signs Experimental Drug Licensing Agreement With 3SBio
Pfizer inks Experimental Drug Licensing Deal With China-based company 3SBio.
Pfizer signs $6bn licensing deal with China's 3SBio for cancer drug
Pfizer Inc (NYSE:PFE, ETR:PFE) has agreed a licensing deal worth up to $6 billion with Chinese biopharmaceutical group 3SBio to develop and commercialise an experimental cancer treatment. The drug, SSGJ-707, is currently in clinical trials in China for use against lung, colorectal and gynaecological cancers.
PFE vs. MRK: Which Oncology Drug Giant is a Better Buy Now?
Both PFE and MRK have strong product and pipeline portfolios in oncology.
Pfizer's Turnaround Story Is Stronger Than You Think
On April 29, 2025, Pfizer beat consensus EPS estimates for the twelfth consecutive quarter by a wide margin, creating a divergence with its stock price, which continues to move sideways. I was pleasantly surprised by the strong performance of Pfizer's oncology and cardiovascular franchises, as well as the positive effects of its cost-cutting program. So, the Vyndaqel family's sales amounted to about $1.49 billion, increasing by 30.7% year-on-year, despite competition from BridgeBio's Attruby and Alnylam Pharmaceuticals' Amvuttra.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
New allegations about timing of Pfizer Covid vaccine passed to House panel
A former Pfizer scientist said the timing of the 2020 vaccine results “wasn't a coincidence,” according to allegations provided by a rival drugmaker.
EU court annuls rejection of bid for EU's von der Leyen vaccine messages with Pfizer
Europe's second-top court on Wednesday dismissed the European Commission's rejection of a New York Times' request to access text messages between its President Ursula von der Leyen and Pfizer CEO Albert Bourla on the purchase of billions of euros of COVID-19 vaccines.
PFE vs. LLY: Which Stock Is the Better Value Option?
Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Eli Lilly (LLY). But which of these two companies is the best option for those looking for undervalued stocks?
Should Value Investors Buy Pfizer (PFE) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Pfizer (NYSE:PFE) Hasn't Been This Cheap in 13 Years. Time to Buy?
Pfizer (NYSE:PFE) is one of the world's largest pharmaceutical companies, but at $22.59 per share as of this writing, the stock trades at its lowest levels in 13 years.
Pfizer (PFE) Just Overtook the 20-Day Moving Average
From a technical perspective, Pfizer (PFE) is looking like an interesting pick, as it just reached a key level of support. PFE recently overtook the 20-day moving average, and this suggests a short-term bullish trend.
Can Pfizer (PFE) Climb 25.14% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for Pfizer (PFE) points to a 25.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
